Empagliflozin for Cardiovascular Disease
This trial will evaluate the effects of empagliflozin on cardiac structure, function, and circulating biomarkers in patients without diabetes but with cardiovascular risk factors.
- Cardiovascular Disease
- Left Ventricular Hypertrophy
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this research the initial foray into such a field of study?
"To date, there are 49 ongoing studies for Empagliflozin in 43 nations and 237 cities. This drug was first trialed by Boehringer Ingelheim back in 2018 with 175 participants and successfully attained Phase 3 approval status. Since then, an impressive 18,466 trials have been finished."
Are there any open slots to participate in this experiment?
"Affirmative. Records on clinicaltrials.gov confirm that this medical research is currently enrolling individuals, with the initial posting taking place on April 1st 2021 and the most recent edit occurring on June 14th 2021. This investigation requires 164 people to be recruited from 3 distinct locations."
What is the current participation rate for this research endeavor?
"Yes, the information available on clinicaltrials.gov shows that this experiment is currently searching for participants. It was first posted in April 1st 2021 and has been revised more recently on June 14th of the same year. The trial requires 164 volunteers across 3 locations to be completed successfully."
Is this study open to geriatric patients?
"Patients who are aged between 40 and 80 qualify to be enrolled in this trial."
Have any prior investigations explored Empagliflozin's therapeutic potential?
"Currently, 49 clinical trials for Empagliflozin are in operation with 13 of them being Phase 3. The primary testing location is Quilmes, Maryland, though other research sites exist across the country and total 1,012."
Has the FDA sanctioned Empagliflozin for use yet?
"Through our assessment at Power, we have determined that Empagliflozin is safe enough to receive a score of 3. This conclusion was made due to it being approved for use in Phase 4 clinical trials."
Who is eligible to take part in this clinical trial?
"This clinical trial seeks 164 cardiovascular disease sufferers aged 40-80 to participate. To be eligible, participants must possess ECG evidence of LV hypertrophy as per the Sokolow-Lyon criteria and be willing to comply with scheduled visits and treatments. They also need an increased LVMi ≥96g/m2 for women and ≥116g/m2 for men (as calculated by echocardiogram or cMRI), structural heart disease defined as interventricular septal thickness or posterior wall thickness at end-diastole of ≥11 mm (as measured by 2D echocardiography or"